Showing results (21-30 of 227) with videos related to
Sort By:
Pageof 23
Polskie Archiwum Medycyny Wewnetrznej|May 23, 2015
What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction?Paul A Gurbel, Eliano Pio Navarese, Udaya S TantryReviews in Cardiovascular Medicine|May 7, 2011
The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitorsMatthew J Price, Udaya S Tantry, Paul A GurbelJACC. Cardiovascular Interventions|April 23, 2011
Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanationsUdaya S Tantry, Dean J Kereiakes, Paul A GurbelExpert Opinion on Pharmacotherapy|October 4, 2005
Resistance to antiplatelet drugs: current status and future researchUdaya S Tantry, Kevin P Bliden, Paul A GurbelExpert Opinion on Pharmacotherapy|August 17, 2010
Ticagrelor for the treatment of arterial thrombosisPaul A Gurbel, Dean J Kereiakes, Udaya S TantryInterventional Cardiology Clinics|June 6, 2017
Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?Udaya S Tantry, Eliano P Navarese, Paul A GurbelJournal of the American College of Cardiology|December 13, 2006
Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b studyPaul A Gurbel, Kevin P Bliden, Udaya S TantryExpert Opinion on Investigational Drugs|January 25, 2007
AZD6140Udaya S Tantry, Kevin P Bliden, Paul A GurbelPolskie Archiwum Medycyny Wewnetrznej|July 16, 2008
Antiplatelet treatment of cardiovascular disease: a translational research perspectivePaul A Gurbel, Mark J Antonino, Udaya S TantryExpert Opinion on Investigational Drugs|August 9, 2011
Vorapaxar: a novel protease-activated receptor-1 inhibitorPaul A Gurbel, Young-Hoon Jeong, Udaya S TantryPageof 23